In conclusion, our studies provide in vitro and in vivo evidence using mouse models of SCD that ET-1 is a novel regulator of MHC class II promoter activity and suggest that ET-1 receptor blockade represents a novel therapeutic approach to improve immune function and inflammatory responses in SCD. This evidence concerns the gene HLA-C and Schnyder corneal dystrophy.